Display Settings:

Format

Send to:

Choose Destination
    Ann Pharm Fr. 2006 Mar;64(2):87-96.

    [Anti-tumor immunotherapy against multidrug resistance].

    [Article in French]

    Source

    Laboratoire de Biochimie EA 3796, Ufr de Pharmacie, Ifr 53 Biomolécules, 3, avenue du Maréchal Juin, F 51096 Reims Cedex. claudie.madoulet@univ.reims.fr

    Abstract

    Overexpression of a membrane glycoprotein (P170) represents the most common multidrug resistance (MDR) mechanism in cancer therapy. Specific autoantibodies to extracellular loops 1, 2 and 4 of murine P170 are elicited in mice using palmitoylated synthetic peptides reconstituted in liposomes with or without Lipid A and resuspended in alum. IgM antibodies are detected 14 days following the first injection and IgG1 become predominant after the third challenge. Animals do not show any autoimmunity symptoms or induced toxicity up to 18 months after the immunization. Previous immunizations of mice using liposomes with mdr1 peptides efficiently improve chemotherapy with doxorubicin and vinblastine against P388 R cells with a 77% increase of survival half time in the immunized group. Sera from immunized mice are also effective in reducing cellular resistance to vinblastine and doxorubicin in vitro. Taken together these data suggest that this immunization approach might have potential clinical applications.

    PMID:
    16568009
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Masson (France)

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk